NCT03192059View on ClinicalTrials.gov

Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Cervical CancerEndometrial CancerUterine Cancer
Interventions
DRUG

Pembrolizumab

Efficacy of the combined treatment

RADIATION

Radiation

Efficacy of the combined treatment

DRUG

Vitamin D

Efficacy of the combined treatment

DRUG

Aspirin

Efficacy of the combined treatment

DRUG

Lansoprazole

Efficacy of the combined treatment

DRUG

Cyclophosphamide

Efficacy of the combined treatment

DIETARY_SUPPLEMENT

Curcumin

Efficacy of the combined treatment

Trial Locations (4)

1000

Institut Jules Bordet, Brussels

9000

University Hospital Gent, Ghent

Unknown

University Hospital Antwerp, Antwerp

CMSE Namur, Namur

All Listed Sponsors
collaborator

Kom Op Tegen Kanker

OTHER

collaborator

Anticancer Fund, Belgium

OTHER

lead

University Hospital, Ghent

OTHER

NCT03192059 - Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer | Biotech Hunter | Biotech Hunter